Jason Bhardwaj and Peter Diamandis

Jason Bhardwaj and Peter Diamandis

Summary of Jason Bhardwaj’s video at the bottom of this post:

  • Follica FDA approval targeted for 2023.
  • Looks like Phase 3 trials need to start quickly. They were expected to start in 2019-2020, however got postponed.
  • 6 short in-office treatments.
  • Cost = $3,000.
  • 75% opportunity of strong hair growth effect. 25% opportunity of modest impact.


Of all the business that I have actually covered on this blog, Follica (majority owned by PureTech) is by far the most aggravating. The business was founded in 2005 and its CEO is Jason Bhardwaj. I have actually covered Follica routinely given that this blog was incepted in August 2013.

Regular readers (and myself) expected Phase 3 clinical trials of Follica’s drug-device to have actually been finished a minimum of 2-3 years ago. Yet here we are in 2022, getting a poster rather. The company’s innovation (a scalp injuring device) is fairly simple in concept.

The purposeful scalp wounding and injury phenomenon has actually been shown to grow hair in numerous research studies (see my post on at-home microneedling). Not totally surprising, considering that even friction from long-lasting cast usage has actually typically grown hair in individuals.

Follica’s gadget is not likely to require any kind of difficulties in being authorized by the US FDA, as the potential for side effects appears negligible. Additionally, all indications are that the company will at first just use Minoxidil in mix with the device. Minoxidil was already authorized by the FDA to deal with male pattern hair loss in 1988. In reality, people are now progressively taking off-label oral Minoxidil to treat their hair loss.

Jason Bhardwaj Presentation

Yet I keep covering Follica and giving them the advantage of doubt. Future hair cloning and hair reproduction related hair loss treatments will constantly have the capacity of significant side effects. Not to discuss significant expense in the initial years. New medications will likewise be met with some trepidation when in concerns long-term side effects. In contrast, wounding associated adverse effects will probably be restricted to minor scalp bleeding. And some scalp skin deterioration in the worst cases.

Just recently, I found the below (see bottom of post) video discussion from Follica CEO Jason Bhardwaj. It is on Peter Diamandis’s YouTube channel. The discussion happened fairly just recently and it is the very first time that I have actually seen Mr. Bhardwaj talk. I am assuming that Mr. Diamandis set up the conference where the below video was recorded.

Peter Diamandis Likes Me

A funny story: In 2008, I flew cross nation to participate in the Singularity Summit (started by Ray Kurzweil) in California. After the occasion was over, among the younger men that I befriended invited me to a mini-conference and dinner that he was organizing in a large personal room in a dining establishment.

Little did I know that simply 20 or so people would remain in that space. As quickly as I entered, Mr. Diamandis (at the head of the table) approached me and shook my hand strongly and gave me a huge smile. Within a few minutes, it became clear to me that this was a major donor meeting. I immediately left the room after informing my organizer buddy. Even he seemed a bit unsure and in awe. To this day, I have no idea why he invited me, knowing that I was a young almost pauper at the time.

Having stated that, Mr. Diamandis is known as Mr. Optimism. He is constantly smiling and overly optimistic about whatever. You never read or hear even one cynical declaration from him on Twitter or in his numerous YouTube video looks.

YouTube Video